90 related articles for article (PubMed ID: 17285317)
1. Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors.
Stinchcombe TE; Socinski MA; Walko CM; O'Neil BH; Collichio FA; Ivanova A; Mu H; Hawkins MJ; Goldberg RM; Lindley C; Dees EC
Cancer Chemother Pharmacol; 2007 Oct; 60(5):759-66. PubMed ID: 17285317
[TBL] [Abstract][Full Text] [Related]
2. A phase I and pharmacokinetic study of indisulam in combination with carboplatin.
Dittrich C; Zandvliet AS; Gneist M; Huitema AD; King AA; Wanders J
Br J Cancer; 2007 Feb; 96(4):559-66. PubMed ID: 17285128
[TBL] [Abstract][Full Text] [Related]
3. Repeated blood-brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial.
Sonabend AM; Gould A; Amidei C; Ward R; Schmidt KA; Zhang DY; Gomez C; Bebawy JF; Liu BP; Bouchoux G; Desseaux C; Helenowski IB; Lukas RV; Dixit K; Kumthekar P; Arrieta VA; Lesniak MS; Carpentier A; Zhang H; Muzzio M; Canney M; Stupp R
Lancet Oncol; 2023 May; 24(5):509-522. PubMed ID: 37142373
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of ombrabulin in combination with paclitaxel and carboplatin in Japanese patients with advanced solid tumors.
Matsumoto K; Sunaga Y; Ecstein-Fraisse E; Fujiwara K
Int J Gynecol Cancer; 2024 Apr; 34(4):586-593. PubMed ID: 37989482
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin.
Zandvliet AS; Schellens JH; Dittrich C; Wanders J; Beijnen JH; Huitema AD
Br J Clin Pharmacol; 2008 Oct; 66(4):485-97. PubMed ID: 18637887
[TBL] [Abstract][Full Text] [Related]
6. First line treatment of advanced non-small-cell lung cancer - specific focus on albumin bound paclitaxel.
Gupta N; Hatoum H; Dy GK
Int J Nanomedicine; 2014; 9():209-21. PubMed ID: 24399877
[TBL] [Abstract][Full Text] [Related]
7. A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusion.
Paik PK; James LP; Riely GJ; Azzoli CG; Miller VA; Ng KK; Sima CS; Heelan RT; Kris MG; Moore E; Rizvi NA
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1331-7. PubMed ID: 21461889
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors.
Azad N; Perroy A; Gardner E; Imamura CK; Graves C; Sarosy GA; Minasian L; Kotz H; Raggio M; Figg WD; Kohn EC
Cancer Biol Ther; 2009 Oct; 8(19):1800-5. PubMed ID: 19738417
[TBL] [Abstract][Full Text] [Related]
9. Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer.
Miele E; Spinelli GP; Miele E; Tomao F; Tomao S
Int J Nanomedicine; 2009; 4():99-105. PubMed ID: 19516888
[TBL] [Abstract][Full Text] [Related]
10. Myelosuppression Caused by Nanoparticle Albumin-Bound Paclitaxel in the Northern Chinese Population and the Role of Body Composition.
Shi Y; Guo J; Jiang Y; Zhao J; Li J; Shen J; Jin G; Bai X; Li Q
J Clin Pharmacol; 2023 Sep; 63(9):1009-1016. PubMed ID: 37128692
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy.
Scripture CD; Figg WD; Sparreboom A
Ther Clin Risk Manag; 2005 Jun; 1(2):107-14. PubMed ID: 18360550
[TBL] [Abstract][Full Text] [Related]
12. Research trend of albumin-bound paclitaxel for the treatment of lung cancer: A 20-year investigation.
Wang L; Zhao G; Fang H; Deng P
Asian J Surg; 2024 Apr; 47(4):2091-2092. PubMed ID: 38242788
[No Abstract] [Full Text] [Related]
13. A pilot study of chemotherapy combinations in rats: Focus on mammary cancer treatment in female dogs.
Silva LP; Yamamoto PA; Machado MCA; Neves FMF; Azeredo FJ; Dos Santos Silva ACS; Hlavac N; de Melo Soares D; Godoy ALPC; Estrela-Lima A
Res Vet Sci; 2023 Mar; 156():14-21. PubMed ID: 36738520
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.
Von Hoff DD; Ramanathan RK; Borad MJ; Laheru DA; Smith LS; Wood TE; Korn RL; Desai N; Trieu V; Iglesias JL; Zhang H; Soon-Shiong P; Shi T; Rajeshkumar NV; Maitra A; Hidalgo M
J Clin Oncol; 2011 Dec; 29(34):4548-54. PubMed ID: 21969517
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced cancers and predominant liver metastases.
Tsimberidou AM; Ye Y; Wheler J; Naing A; Hong D; Nwosu U; Hess KR; Wolff RA
Cancer Chemother Pharmacol; 2013 Apr; 71(4):955-63. PubMed ID: 23377373
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer.
Socinski MA; Langer CJ; Okamoto I; Hon JK; Hirsh V; Dakhil SR; Page RD; Orsini J; Zhang H; Renschler MF
Ann Oncol; 2013 Feb; 24(2):314-321. PubMed ID: 23123509
[TBL] [Abstract][Full Text] [Related]
17. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.
Ko AH; Truong TG; Kantoff E; Jones KA; Dito E; Ong A; Tempero MA
Cancer Chemother Pharmacol; 2012 Dec; 70(6):875-81. PubMed ID: 23053263
[TBL] [Abstract][Full Text] [Related]
18. First-line carboplatin/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience.
Parisi A; Palluzzi E; Cortellini A; Sidoni T; Cocciolone V; Lanfiuti Baldi P; Porzio G; Ficorella C; Cannita K
Clin Transl Oncol; 2020 Jan; 22(1):158-162. PubMed ID: 31041717
[TBL] [Abstract][Full Text] [Related]
19. Lessons learned from immunological characterization of nanomaterials at the Nanotechnology Characterization Laboratory.
Dobrovolskaia MA
Front Immunol; 2022; 13():984252. PubMed ID: 36304452
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
